<PAGE> 1
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934
FILED BY THE REGISTRANT [X] FILED BY A PARTY OTHER THAN THE REGISTRANT [ ]
--------------------------------------------------------------------------------
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Under Rule 14a-12
ImmunoGen, Inc.
(Name of Registrant as Specified In Its Charter)
ImmunoGen, Inc.
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
1) Title of each class of securities to which transaction applies:
2) Aggregate number of securities to which transaction applies:
3) Per unit price or other underlying value of transaction computed pursuant
to Exchange Act
Rule 0-11 (Set forth the amount on which the filing fee is calculated and
state how it was determined):
4) Proposed maximum aggregate value of transaction:
5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
1) Amount Previously Paid:
2) Form, Schedule or Registration Statement No.:
3) Filing Party:
4) Date Filed:
--------------------------------------------------------------------------------
<PAGE> 2
[IMMUNOGEN, INC. LOGO]
--------------------------------------------------------------------------------
128 SIDNEY STREET, CAMBRIDGE, MA 02139 TEL:(617)995-2500 FAX:(617)995-2510
October 17, 2000
Dear Shareholder:
You are cordially invited to attend the 2000 Annual Meeting of Shareholders
of ImmunoGen, Inc. (the "Company") to be held at 10:00 a.m., Boston time, on
Tuesday, November 14, 2000 at the offices of the Company, 128 Sidney Street,
Cambridge, Massachusetts.
The accompanying Notice of Annual Meeting of Shareholders and Proxy
Statement describe the matters that will be presented at the Annual Meeting. At
the Annual Meeting, six members will be elected to the Board of Directors. The
Board of Directors recommends the election of the six nominees named in the
enclosed Proxy Statement.
Whether you plan to attend the Annual Meeting or not, please complete, sign
and date the enclosed Proxy and return it in the envelope enclosed for this
purpose. This will ensure your proper representation at the Annual Meeting.
Sincerely,
/S/ MITCHEL SAYARE
MITCHEL SAYARE
President, Chief Executive Officer
and Chairman of the Board
YOUR VOTE IS IMPORTANT. PLEASE RETURN YOUR PROXY PROMPTLY.
<PAGE> 3
IMMUNOGEN, INC.
128 SIDNEY STREET
CAMBRIDGE, MASSACHUSETTS 02139
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD ON NOVEMBER 14, 2000
To Shareholders of
ImmunoGen, Inc.:
Notice is hereby given that the Annual Meeting of Shareholders of
ImmunoGen, Inc. (the "Company") will be held at the offices of the Company, 128
Sidney Street, Cambridge, Massachusetts, on Tuesday, November 14, 2000 at 10:00
a.m., Boston time, for the following purposes:
1. To fix the number of Directors at six and to elect six Directors to
hold office until the next annual meeting of shareholders and until
their successors are elected and qualified; and
2. To transact such other business as may properly come before the Annual
Meeting or any adjournment(s) thereof.
Only shareholders of record at the close of business on September 18, 2000
will receive notice of the Annual Meeting and be entitled to vote at the Annual
Meeting or any adjournment(s) thereof. The transfer books will not be closed.
You are cordially invited to attend the Annual Meeting in person, if
possible. WHETHER YOU PLAN TO ATTEND THE ANNUAL MEETING OR NOT, PLEASE COMPLETE,
SIGN AND DATE THE ENCLOSED PROXY AND RETURN IT IN THE ENVELOPE ENCLOSED FOR THIS
PURPOSE. Your Proxy is revocable at any time prior to the exercise thereof by
written notice received by the Company, by delivery of a duly executed proxy
bearing a later date, or by attending the Annual Meeting and voting in person.
By order of the Board of Directors
/S/ JONATHAN L. KRAVETZ, ESQ.
JONATHAN L. KRAVETZ, ESQ.
Clerk
October 17, 2000
<PAGE> 4
IMMUNOGEN, INC.
128 SIDNEY STREET
CAMBRIDGE, MASSACHUSETTS 02139
-------------------------------
PROXY STATEMENT
-------------------------------
------------------------------------------------------------
ANNUAL MEETING OF SHAREHOLDERS
------------------------------------------------------------
TO BE HELD ON NOVEMBER 14, 2000
GENERAL INFORMATION
Introduction. This Proxy Statement is furnished in connection with the
solicitation by and on behalf of the Board of Directors (the "Board") of
ImmunoGen, Inc. (the "Company") of Proxies for use at the Annual Meeting of
Shareholders of the Company to be held at the offices of the Company, 128 Sidney
Street, Cambridge, Massachusetts on Tuesday, November 14, 2000 at 10:00 a.m.,
Boston time, and at any adjournments thereof (the "Meeting"), and, together with
the enclosed Form of Proxy and Annual Report to Shareholders for the Fiscal Year
ended June 30, 2000, is being mailed to the shareholders on or about October 17,
2000. The Annual Report does not form any part of this Proxy Statement.
Voting and Revocability of Proxies. When the Proxy of a shareholder is
duly executed and returned, the shares represented thereby will be voted in
accordance with the voting instructions given on the Proxy by the shareholder.
If no such voting instructions are given on a Proxy with respect to one or more
proposals, the shares represented by that Proxy will be voted, with respect to
the election of Directors, for the nominees named herein, and, with respect to
other proposals, in accordance with the recommendations of the Board. Any Proxy
given pursuant to this solicitation may be revoked by the person giving it at
any time before its use by delivering to the Company a written notice of
revocation or a duly executed Proxy bearing a later date, or by attending the
Meeting and voting in person.
Cost of Solicitation. The Company will pay the entire cost of this
solicitation. In addition, the Company may reimburse brokerage firms and other
persons representing beneficial owners of shares for their reasonable expenses
in forwarding solicitation material to such beneficial owners. Solicitation of
Proxies by mail may be supplemented by telephone, telegram, telex, telecopy, or
personal solicitation by Directors, officers or employees of the Company. No
additional compensation will be paid for such solicitation.
Quorum and Voting. Only shareholders of record of the Company's 34,091,415
shares of Common Stock, $.01 par value per share (the "Common Stock"),
outstanding as of the close of business on September 18, 2000 will be entitled
to vote. Each share of Common Stock is entitled to one vote at the Meeting. The
presence, in person or by Proxy, of the holders of a majority of the outstanding
shares of Common Stock entitled to vote is necessary to constitute a quorum at
the Meeting. No appraisal rights exist for any action to be taken at the
Meeting.
Nominees for election as directors at the meeting will be elected by a
plurality of the votes of the shares present in person or represented by proxy
at the meeting. Withholding authority to vote for a nominee for director will
have no effect on the outcome of the vote. If you hold your shares of Common
Stock through a broker, bank or other representative, generally the broker or
your representative may only vote the Common Stock that it holds for you in
accordance with your instructions. However, if it has not timely received your
instructions, the broker or your representative may vote on certain matters for
which it has discretionary voting
<PAGE> 5
authority. If a broker or your representative cannot vote on a particular matter
because it does not have discretionary voting authority, this is a "broker
non-vote" on that matter. As to the election of directors, broker non-votes are
not deemed to be present or represented and are not entitled to vote, and
therefore will have no effect on the outcome of the vote.
PRINCIPAL SHAREHOLDERS
The following table sets forth certain information regarding the beneficial
ownership of shares of Common Stock as of September 18, 2000 by (i) each person
or entity known by the Company to be a beneficial owner of more than 5% of the
outstanding shares of Common Stock, (ii) each Director and nominee for Director
of the Company, (iii) each executive officer of the Company named in the Summary
Compensation Table below, and (iv) all current executive officers and Directors
of the Company as a group. Except as otherwise indicated, each shareholder has
sole voting and investment power with respect to the shares beneficially owned.
<TABLE>
<CAPTION>
PERCENTAGE
NUMBER OF SHARES OF SHARES
NAME AND ADDRESS OF BENEFICIALLY BENEFICIALLY
BENEFICIAL OWNER* OWNED(1) OWNED(1)
------------------- ---------------- ------------
<S> <C> <C>
Capital Ventures International(2)........................... 2,347,117 6.9%
One Capitol Place, P.O. Box 1787 GT
Grand Cayman, Cayman Islands, BWI
Mitchel Sayare(3)........................................... 820,445 2.4%
Walter A. Blattler(4)....................................... 464,506 1.4%
David W. Carter(5).......................................... 40,834 **
Michael R. Eisenson(6)...................................... 0 --
Mark Skaletsky.............................................. 0 --
Stuart F. Feiner(7)......................................... 19,166 **
Kathleen A. Carroll(8)...................................... 46,234 **
Pauline Jen Ryan(9)......................................... 10,000 **
John M. Lambert(10)......................................... 263,203 **
All current executive officers and Directors as a group (9
persons)(11).............................................. 1,664,388 4.9%
</TABLE>
---------------
* Addresses are given for beneficial owners of more than 5% of the
outstanding Common Stock only.
** Represents beneficial ownership of less than 1% of the Common Stock.
(1) Share ownership includes shares of Common Stock issuable upon exercise of
certain outstanding options and warrants as described in the footnotes
below.
(2) Consists of 2,347,117 shares of Common Stock which Capital Ventures
International ("CVI") may acquire upon the exercise of warrants to purchase
Common Stock. The Restated Articles of Organization, as amended, of the
Company and the warrants held by CVI (the "CVI Warrants") limit the right
of CVI to exercise the CVI Warrants such that the maximum number of shares
of the Common Stock which may at any time be deemed to be beneficially
owned by CVI upon the exercise of the CVI Warrants may not, together with
any other shares of Common Stock then owned by CVI, exceed 9.9% of the then
issued and outstanding shares of Common Stock.
(3) Includes 618,945 shares of Common Stock which Mr. Sayare may acquire upon
the exercise of options within 60 days after September 18, 2000.
2
<PAGE> 6
(4) Includes 381,445 shares of Common Stock which Dr. Blattler may acquire upon
the exercise of options within 60 days after September 18, 2000.
(5) Consists of 40,834 shares of Common Stock which Mr. Carter may acquire upon
the exercise of options within 60 days after September 18, 2000.
(6) Michael R. Eisenson, a Director of the Company, is President and Chief
Executive Officer of Charlesbank Capital Partners, LLC, the successor to
Harvard Private Capital Group, Inc. and the investment advisor to Aeneas
Venture Corporation ("Aeneas"). Mr. Eisenson owns no shares of Common Stock
and disclaims beneficial ownership of the shares owned by Aeneas. Pursuant
to an agreement among the Company, Aeneas and Mr. Eisenson, grants of stock
options in connection with Mr. Eisenson's service as a Director are granted
directly to Aeneas. Pursuant to such grants, Aeneas may acquire 70,000
shares of Common Stock within 60 days after September 18, 2000.
(7) Stuart F. Feiner, a Director of the Company, is Executive Vice President,
General Counsel and Secretary of Inco Limited. He is also Chairman of the
general partner of North American Partners Limited Partnership II, which
owns 19 shares of Common Stock. Mr. Feiner disclaims beneficial ownership
of the shares of Common Stock held by each of such shareholders. Mr. Feiner
individually did not own any shares of Common Stock as of September 18,
2000. He is also named as direct owner of non-qualified options to acquire
95,000 shares of Common Stock granted by the Company in each of July 1992,
July 1996, December 1997 and July 1998. Pursuant to such option grants, Mr.
Feiner may directly acquire 70,001 shares of Common Stock within 60 days
after September 18, 2000. However, Mr. Feiner disclaims certain beneficial
interest in the derivative securities and underlying shares pursuant to an
arrangement made between Mr. Feiner and Inco Limited, whereby Mr. Feiner
assigned the options to acquire a total of 53,334 shares of Common Stock to
that entity.
(8) All shares were owned on September 18, 2000. Ms. Carroll resigned her
position with the Company on August 11, 2000.
(9) Includes 10,000 shares of Common Stock which Ms. Ryan may acquire upon the
exercise of options within 60 days after September 18, 2000.
(10) Includes 231,912 shares of Common Stock which Dr. Lambert may acquire upon
the exercise of options within 60 days after September 18, 2000.
(11) See also footnotes (3) through (7), (9), and (10).
3
<PAGE> 7
INFORMATION ABOUT DIRECTORS AND CURRENT EXECUTIVE OFFICERS
The names of the Directors and certain other information about them as of
the date hereof are set forth below:
<TABLE>
<CAPTION>
NAME OF DIRECTOR AGE PRINCIPAL OCCUPATIONS DURING AT LEAST THE LAST FIVE YEARS
---------------- --- ---------------------------------------------------------
<S> <C> <C>
Mitchel Sayare........... 52 Mitchel Sayare, Chief Executive Officer, a Director since
1986 and Chairman of the Board since 1989, joined the
Company in 1986. From 1986 until 1992, and currently
since 1994, Mr. Sayare has served as President of the
Company. From 1982 to 1985, Mr. Sayare was Vice President
for Development at Xenogen, Inc., a biotechnology company
specializing in monoclonal antibody-based diagnostic
systems for cancer. From 1977 to 1982, Mr. Sayare was
Assistant Professor of Biophysics and Biochemistry at the
University of Connecticut. He holds a Ph.D. in
Biochemistry from Temple University School of Medicine.
Mr. Sayare serves on the Board of Directors of ImmuCell
Corporation, in addition to a number of private
companies.
Walter A. Blattler....... 51 Walter A. Blattler, Ph.D., elected a Director in
September 1995, served as Vice President, Research and
Development of the Company from 1987 to October 1994 and
as the Company's Senior Vice President, Research and
Development from October 1994 to October 1996. Since
1996, Dr. Blattler has served as the Company's Executive
Vice President, Science and Technology. Dr. Blattler
joined the Company in October 1987. From 1981 to 1987,
Dr. Blattler was chief scientist for the ImmunoGen-
supported research program at the Dana-Farber Cancer
Institute. Dr. Blattler received his Ph.D. from the Swiss
Federal Institute of Technology in Zurich in 1978.
David W. Carter.......... 61 David W. Carter, a Director since June 1997, is Co-Chief
Executive Officer and a director of Xenogen, Inc., which
he joined in 1997. From 1991 to 1997, Mr. Carter was the
President and Chief Executive Officer of Somatix Therapy
Corporation. Mr. Carter also serves on the Board of
Directors of Cell Genesys, Inc.
Michael R. Eisenson...... 45 Michael R. Eisenson, a Director since 1986, is President
and Chief Executive Officer of Charlesbank Capital
Partners, LLC (the successor to Harvard Private Capital
Group, Inc., which he joined in 1986). Between 1981 and
1986, Mr. Eisenson held the position of Manager, Boston
Consulting Group. Mr. Eisenson serves on the Boards of
Directors of CCC Information Services Group Inc., Playtex
Products, Inc., and United Auto Group, Inc.
</TABLE>
4
<PAGE> 8
<TABLE>
<CAPTION>
NAME OF DIRECTOR AGE PRINCIPAL OCCUPATIONS DURING AT LEAST THE LAST FIVE YEARS
---------------- --- ---------------------------------------------------------
<S> <C> <C>
Stuart F. Feiner......... 52 Stuart F. Feiner, a Director since 1984, has been
Executive Vice President, General Counsel and Secretary
of Inco Limited since August 1993, after having served as
Vice President, General Counsel and Secretary of Inco
Limited from April 1992 to August 1993. From January 1984
until April 1992, Mr. Feiner was President of Inco
Venture Capital Management, the venture capital unit of
Inco Limited. Mr. Feiner serves on the board of directors
of certain private companies funded by Inco Venture
Capital Management.
Mark Skaletsky........... 51 Mark Skaletsky, a Director since March 2000, has been
President, Chief Executive Officer, and a Director of
GelTex Pharmaceuticals, Inc. since 1993. From 1988 to
1993, he was Chairman and Chief Executive Officer of
Enzytech, Inc., a biotechnology company, and from 1983 to
1988 he was President and Chief Operating Officer of
Biogen, Inc., also a biotechnology company. He is a
director of Isis Pharmaceuticals, Inc. and Microcide
Pharmaceuticals, Inc.
</TABLE>
The names of, and certain other information as of the date hereof
regarding, each current executive officer of the Company who is not a member of
the Board is set forth below. Executive officers serve at the pleasure of the
Board.
<TABLE>
<CAPTION>
NAME OF EXECUTIVE OFFICER AGE PRINCIPAL OCCUPATIONS DURING AT LEAST THE LAST FIVE YEARS
------------------------- --- ---------------------------------------------------------
<S> <C> <C>
John M. Lambert, Ph.D.... 49 John M. Lambert, Ph.D., Senior Vice President,
Pharmaceutical Development, joined the Company in 1987.
Dr. Lambert served as the Company's Senior Director of
Research from October 1994 to November 1996. Prior to
joining ImmunoGen, Dr. Lambert was Assistant Professor of
Pathology at the Dana-Farber Cancer Institute, where he
worked on the research program supported by ImmunoGen.
Dr. Lambert received his Ph.D. in Biochemistry from
Cambridge University in England.
Pauline Jen Ryan......... 33 Pauline Jen Ryan, Vice President, Business Development,
rejoined the Company in May of 1999. From 1998 to 1999,
Ms. Ryan was a Vice President of Capital Management
Consulting, Inc., a biomedical consulting firm. From 1994
to 1997, she was Director of Business Development of
Organogenesis, Inc., a biotechnology company. Ms. Ryan
holds a Masters of Business Administration from
Northwestern University's Kellogg Graduate School of
Management.
</TABLE>
5
<PAGE> 9
EXECUTIVE COMPENSATION
COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION((1))
The Compensation Committee of the Board (the "Committee") is comprised
entirely of non-employee Directors. The Committee determines the base salaries
of the Company's executive officers and the amount of annual bonus awards, if
any, to be paid to the executive officers. In addition, the Committee
administers the Company's Restated Stock Option Plan, as amended, (the "Plan")
under which stock options may be granted to executive officers and other
employees of the Company, as well as to non-employee Directors.
COMPENSATION POLICY AND COMPONENTS OF COMPENSATION
The Committee's fundamental executive compensation philosophy is to enable
the Company to attract and retain key executives, and to motivate those
executives to achieve the Company's long-term objective of becoming a profitable
company. Attracting and retaining key executives is important to any
organization. However, it is an especially difficult challenge in the
biotechnology industry, where executives are required to remain focused and
committed throughout many years of product development and financial
instability.
Each executive officer's compensation package is reviewed at least annually
and may be comprised of up to three components: base salary, incentive cash
bonuses and stock options. In addition, the Company's executive officers are
eligible to participate in all employee benefit programs generally available to
all other ImmunoGen employees.
Progress toward the Company's broad strategic goal of becoming a profitable
biopharmaceutical company is measured by specific corporate objectives and
annual milestones. Personal objectives and milestones by which individual
executives of the Company are evaluated fit within the framework of the
Company's overall goals and objectives. Subjective factors, such as changes in
business conditions and other relevant external circumstances, are also taken
into consideration. The Company believes the nature of its specific goals and
milestones and progress toward their achievement constitute proprietary and
confidential information, the disclosure of which would place the Company at a
competitive disadvantage.
BASE SALARIES OF EXECUTIVE OFFICERS
The Committee sets the salaries of executive officers by reviewing
independently-prepared surveys of biotechnology industry compensation as well as
other available information on the base salaries of executive officers in
comparable positions in other biotechnology companies. There is substantial
overlap between biotechnology companies, the compensation practices of which are
reflected in such surveys, and the biotechnology companies included in the
Nasdaq Pharmaceutical Stocks Total Return Index (see "Stock Price Performance
Graph"). Comparative factors considered include, but are not limited to, company
size, stage of development of a company's products and geographic location. The
Committee uses the collected data as well as the experience of the members of
the committee in hiring and managing personnel to set salaries. The Committee
also takes into account, for both current and new executive officers,
competitive industry factors, breadth of experience, length of service, and
recent individual performance. It is not the Company's intent to establish fixed
levels of compensation in general or for specific positions, but rather to
establish compensation on a case-by-case basis as recommended by management and
confirmed by the Committee. The Company's executive salaries, as currently paid,
are estimated to range from the 50th
---------------
(1) The report of the Compensation Committee of the Board shall not be deemed
incorporated by reference by any general statement incorporating by
reference this Proxy Statement into any filing under the Securities Act of
1933, as amended, or under the Securities Exchange Act of 1934, as amended,
except to the extent that the Company specifically incorporates this report
by reference.
6
<PAGE> 10
percentile to the 75th percentile of comparable biotechnology companies. The
salary of the Company's Chairman of the Board, President and Chief Executive
Officer is estimated to be in the 75th percentile of such range.
In certain cases initial annual base compensation was established pursuant
to employment agreements with executive officers (see "Employment Contracts,
Termination of Employment and Change in Control Agreements"). The terms of such
employment contracts were reviewed and authorized by the Board (including
members of the Committee but excluding any interested officer) and were
consistent with the Company's compensation policies then in place.
In October 1999, Dr. Blattler's base salary was set at $250,000 annually.
Dr. Lambert's base salary was set at $190,000 during January 2000 and Ms.
Carroll's((1)) was set at $140,000. Ms. Ryan's base salary was set at $160,000
in February 2000.
BONUS AWARDS
The Company does not have formal incentive or bonus plans for executives
and, for the three fiscal years ended June 30, 2000, no bonuses have been
awarded to any current executive officer of the Company.
STOCK OPTION PLAN
Subject to the provisions of the Plan, the Committee has the authority to
determine the terms under which options are granted and the individuals to whom
such options may be granted. The Committee believes that equity participation is
a key component of its executive compensation program. The stock option program
is the Company's major long-term incentive plan, designed to retain executive
officers and other employees and motivate them to enhance shareholder value by
aligning the long-term interests of the Company's employees with those of its
shareholders. Stock options provide an effective long-term incentive for all
employees to create shareholder value since the full benefit of the options
cannot be realized unless an appreciation in the price of the Company's Common
Stock occurs. The executive officers participate in the Plan in the same manner
as all of the Company's full-time employees. Initial stock option awards for new
employees, which are individually determined prior to employment, are derived
from the employee's anticipated contribution to the Company's growth and are
designed to be competitive with awards granted by other biotechnology companies.
Subsequent annual stock option awards are based on historical levels of prior
grants, position within the Company and individual performance. For fiscal year
1998, all current executive officers were awarded stock options in August and
December of 1997. For fiscal years 1999 and 2000, stock options were awarded to
all current executive officers in January 1999 and January 2000, respectively.
All options are issued with exercise prices equal to the fair market value of
the Company's Common Stock on the date of grant. The options granted in fiscal
years 1999 and 2000 vest as to one-third of the shares on each anniversary date
of the date of grant. Vesting of options may be accelerated and options may
become fully exercisable upon the occurrence of certain events such as a change
in control of the Company (see "Employment Contracts, Termination of Employment
and Change in Control Agreements").
In addition to incentive stock options, the Committee also has
discretionary authority under the Plan to grant non-qualified options to certain
individuals, including executive officers of the Company. Of the current
executive officers, only Mr. Sayare and Dr. Blattler have been granted
non-qualified options. In each case, the options were granted with exercise
prices equal to the fair market value of the Common Stock on the date of grant
and vested over three years in equal annual installments.
---------------
(1) Ms. Carroll resigned her position with the Company on August 11, 2000.
7
<PAGE> 11
COMPENSATION OF THE CHIEF EXECUTIVE OFFICER
Mr. Sayare's annual base salary has been determined in accordance with the
criteria outlined in other sections of this report, the Committee's evaluation
of the Company's overall performance, and Mr. Sayare's individual performance.
Performance was measured by achievement of certain goals over the last several
years, including the consummation of several significant financing transactions
and the continued development of the Company's key technology platforms. Mr.
Sayare's salary was increased to $330,000 on February 1, 1999.
No cash bonus was paid to Mr. Sayare during fiscal years 1998, 1999, and
2000. No stock options were granted to Mr. Sayare in fiscal 1997. In fiscal
1998, Mr. Sayare was granted options to purchase 75,000 shares and 229,166
shares of Common Stock in each of August 1997 and December 1997, respectively.
In fiscal 1999, Mr. Sayare was awarded options to purchase 85,000 shares of
Common Stock in January 2000. The options granted to Mr. Sayare in fiscal years
1999 and 2000 vest as to one-third of the shares each year after issuance
beginning one year from the date of grant. All options are subject to Mr.
Sayare's continued employment with the Company and were issued with exercise
prices equal to the fair market value of the Common Stock on the date of grant.
CERTAIN AGREEMENTS
The Company has entered into agreements with certain of its executive
officers relating to employment and separation. In making determinations of
salary and benefits to be provided under the aforementioned employment and
separation agreements, the Committee took into consideration contractual
commitments and Company policies. (See "Employment Contracts, Termination of
Employment and Change in Control Agreements").
COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS
DAVID W. CARTER
MICHAEL R. EISENSON
STUART F. FEINER
MARK B. SKALETSKY
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The Committee members during fiscal year 2000 were Messrs. David W. Carter,
Michael R. Eisenson, Stuart F. Feiner, and Mark B. Skaletsky. None of these
Directors is or has been an officer or employee of the Company. Mr. Sayare,
though not a member of the Committee, assists the Committee in determining any
compensation to be awarded to executive officers other than himself. Mr. Sayare
provides supplemental information regarding performance evaluations of executive
officers other than himself.
8
<PAGE> 12
SUMMARY COMPENSATION TABLE
The following table (the "Summary Compensation Table") sets forth certain
information regarding compensation paid during each of the Company's last three
fiscal years to the Company's Chief Executive Officer and to each of the
Company's executive officers, other than the Chief Executive Officer, whose
total annual salary and bonus exceeded $100,000 in fiscal year 2000.
<TABLE>
<CAPTION>
LONG-TERM
COMPENSATION
AWARDS
ANNUAL ------------
COMPENSATION SECURITIES ALL OTHER
NAME AND ------------- UNDERLYING COMPENSATION
PRINCIPAL POSITION YEAR SALARY ($)(1) OPTIONS (#) ($)(2)
------------------ ---- ------------- ------------ ------------
<S> <C> <C> <C> <C>
Mitchel Sayare............................... 2000 330,000 85,000 2,696
Chairman of the Board, Chief Executive 1999 273,000 80,000 3,185
Officer and President 1998 245,000 304,166 2,734
Walter A. Blattler, Ph.D. ................... 2000 262,000 80,000 2,625
Director and Executive Vice President, 1999 201,539 75,000 1,915
Science and Technology 1998 180,000 230,417 1,598
John M. Lambert, Ph.D. ...................... 2000 182,000 70,000 2,400
Vice President, Research and 1999 159,692 54,000 1,370
Development 1998 150,000 141,667 1,232
Kathleen A. Carroll(3)....................... 2000 136,788 30,000 1,977
Vice President, Finance and 1999 110,769 45,000 1,051
Administration 1998 100,000 108,750 360
Pauline Jen Ryan............................. 2000 140,308 25,000 2,014
Vice President, Business Development 1999 13,846 40,000 92
</TABLE>
---------------
(1) Includes amounts, if any, deferred by each individual under the ImmunoGen,
Inc. 401(k) Plan and Trust.
(2) Fiscal year 1999 amounts include term life insurance premiums of $472 for
Mr. Sayare, $440 for Dr. Blattler, $336 for Dr. Lambert, $216 for Ms.
Carroll, and $234 for Ms. Ryan. Also included are matching 401(k)
contributions of $2,224 for Mr. Sayare, $2,185 for Dr. Blattler, $2,064 for
Dr. Lambert, $1,761 for Ms. Carroll, and $1,780 for Ms. Ryan.
(3) Ms. Carroll resigned her position with the Company on August 11, 2000.
9
<PAGE> 13
OPTION GRANTS IN LAST FISCAL YEAR
The following table sets forth information regarding each stock option
granted during fiscal year 2000 to each individual named in the Summary
Compensation Table.
<TABLE>
<CAPTION>
POTENTIAL REALIZABLE
NUMBER OF PERCENT OF VALUE AT ASSUMED
SECURITIES TOTAL OPTIONS ANNUAL RATES OF STOCK
UNDERLYING GRANTED TO PRICE APPRECIATION
OPTIONS EMPLOYEES IN FOR OPTION TERM(3)
GRANTED FISCAL YEAR EXERCISE EXPIRATION ----------------------
NAME (#)(1) (%) PRICE ($)(2) DATE 5% ($) 10% ($)
---- ---------- ------------- ------------ ---------- --------- ---------
<S> <C> <C> <C> <C> <C> <C>
Mitchel Sayare............. 85,000 14.3 6.781 01/19/10 362,485 918,609
Walter A. Blattler,
Ph.D. ................... 80,000 13.4 6.781 01/19/10 341,163 864,573
John M. Lambert, Ph.D. .... 70,000 11.7 6.781 01/19/10 298,517 756,502
Kathleen A. Carroll........ 30,000 5.0 6.781 01/19/10 127,936 324,215
Pauline Jen Ryan........... 25,000 4.2 6.781 01/19/10 106,613 270,179
</TABLE>
---------------
(1) Options were granted on January 19, 2000. All options vest ratably over
three years beginning on the date of grant. Under certain circumstances,
vesting of options may be accelerated and options may become fully
exercisable.
(2) The exercise price was equal to the fair market value of the Common Stock on
the date of grant.
(3) Amounts represent hypothetical gains that could be achieved for the
respective options if exercised at the end of the option term. Those gains
are based on assumed rates of stock price appreciation of 5% and 10%
compounded annually from the date the respective options were granted. These
rates of appreciation are mandated by the rules of the Securities and
Exchange Commission and do not represent the Company's estimate or
projection of future Common Stock prices.
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION
VALUES
The following table provides information as to each individual named in the
Summary Compensation Table regarding the number of shares covered by both
exercisable and unexercisable options as of June 30, 2000 and the value of
unexercised options.
<TABLE>
<CAPTION>
NUMBER OF SECURITIES
UNDERLYING UNEXERCISED VALUE OF UNEXERCISED
OPTIONS AT FISCAL IN-THE-MONEY OPTIONS
YEAR-END (#) AT FISCAL YEAR-END ($)(1)
---------------------------- ----------------------------
NAME EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
---- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C>
Mitchel Sayare............................. 593,945 239,721 4,939,627 2,098,259
Walter A. Blattler, Ph.D. ................. 358,112 206,805 3,308,843 1,764,053
John M. Lambert, Ph.D. .................... 215,246 153,221 2,030,266 1,245,010
Kathleen A. Carroll........................ 173,700 30,000 1,785,665 158,445
Pauline Jen Ryan........................... 10,000 55,000 95,945 419,873
</TABLE>
---------------
(1) Value is based on the last sale price per share ($12.0625) on June 30, 2000,
as reported on the Nasdaq National Market, less the applicable option
exercise price. Each option has an exercise price equal to the fair market
value of the Common Stock on the date of grant.
10
<PAGE> 14
EMPLOYMENT CONTRACTS, TERMINATION OF EMPLOYMENT AND CHANGE IN CONTROL AGREEMENTS
The Company entered into employment agreements with Dr. Blattler, Dr.
Lambert, and Ms. Ryan on their respective hire dates. These agreements currently
provide for annual salaries of $250,000 for Dr. Blattler and $190,000 for Dr.
Lambert, and $160,000 for Ms. Ryan. These agreements may be terminated by either
the Company or the executive officer upon 90 days' prior written notice. In
addition, each agreement provides that the Company may terminate the employment
of the executive officer at any time for cause (as defined in the respective
agreements). The agreements with Dr. Blattler and Dr. Lambert also provide that
these executive officers will not engage in any business competitive with the
business of the Company for a period of two years following termination of
employment.
In making determinations of salary and benefits to be provided under the
aforementioned employment agreements, the Committee took into consideration, in
addition to contractual commitments, Company personnel policies.
Contractual language is included in stock option agreements between the
Company and members of its senior management group to the effect that all
unvested options of the affected employee will become immediately exercisable in
instances where:
(i) (A) a person becomes the beneficial owner of fifty percent or more of
the voting securities of the Company, or
(B) the Board approves a consolidation or merger of the Company
whereby the shareholders of the Company would not retain fifty
percent or more of the voting securities of the Company after the
consolidation or merger, and
(ii) (A) a material change is made in the Restated Stock Option Plan or an
option granted thereunder (except as provided in Section 16(b) of
the Plan), or
(B) the affected employee is, within two years, terminated for any
reason other than for cause, then all unvested options of the
affected employee will become immediately exercisable.
11
<PAGE> 15
STOCK PRICE PERFORMANCE GRAPH
The graph and table below compare the cumulative total stockholder return
on an annual basis on the Common Stock for the period from June 30, 1995 through
June 30, 2000 to the cumulative total returns on the Nasdaq Stock Market Index
(U.S.) and the Nasdaq Pharmaceutical Stocks Total Return Index for the same
period.
[LINE GRAPH]
<TABLE>
<CAPTION>
1995 1996 1997 1998 1999 2000
---- ---- ---- ---- ---- ----
<S> <C> <C> <C> <C> <C> <C>
IMMUNOGEN, INC. $100.00 $103.00 $ 40.00 $ 45.00 $ 60.00 $326.00
NASDAQ STOCK MARKET INDEX (U.S.) $100.00 $128.00 $156.00 $206.00 $296.00 $437.00
NASDAQ PHARMACEUTICAL $100.00 $147.00 $150.00 $153.00 $214.00 $481.00
</TABLE>
The above graph and table assume $100 invested on June 30, 1995 with all
dividends reinvested, in each of the Common Stock, the Nasdaq Composite Index
(U.S.) and the Nasdaq Pharmaceutical Stocks Total Return Index. The Nasdaq
Pharmaceutical Stocks Total Return Index was prepared by the Center for Research
in Security Prices. Upon written request by any shareholder, the Company will
promptly provide a list of the companies comprising the Nasdaq Pharmaceutical
Stocks Total Return Index.
PROPOSAL 1: ELECTION OF DIRECTORS
At the Meeting the number of Directors will be fixed at six and six
Directors will be elected to serve until the next annual meeting of shareholders
and until such Directors' successors have been elected and qualified.
The enclosed Proxy, unless authority to vote is withheld, will be voted for
the election of the nominees named herein as Directors of the Company. The
nominees are Mitchel Sayare, Walter A. Blattler, Ph.D., David W. Carter, Michael
R. Eisenson, Stuart F. Feiner, and Mark Skaletsky. The Board has no reason to
believe that any nominee will become unavailable. However, in the event that any
one or more of such nominees shall unexpectedly become unavailable for election,
votes will be cast, pursuant to authority granted by the enclosed Proxy, for
such person or persons as may be designated by the Board.
David W. Carter, Michael R. Eisenson, Stuart F. Feiner, and Mark B.
Skaletsky currently serve on the Company's Audit Committee. The Audit Committee
reviews the engagement of the Company's independent
12
<PAGE> 16
accountants, reviews quarterly and annual financial statements, considers
matters relating to accounting policy and internal controls and reviews the
scope of annual audits.
David W. Carter, Michael R. Eisenson, Stuart F. Feiner, and Mark B.
Skaletsky currently comprise the Compensation Committee. The Compensation
Committee reviews, approves and makes recommendations concerning the Company's
compensation policies, practices and procedures to ensure that the legal and
fiduciary responsibilities of the Board are carried out and that such policies,
practices and procedures contribute to the success of the Company. The
Compensation Committee also administers the Company's Restated Stock Option
Plan.
The Company does not have a standing Nominating Committee.
During the fiscal year ended June 30, 2000, there were five meetings of the
Board and two meetings of the Audit Committee. The Compensation Committee met on
the same dates as the meetings of the Board of Directors. Further, from time to
time, the members of the Board and its Committees acted by unanimous written
consent or actions by the Directors without a meeting pursuant to Massachusetts
law. Messrs. Sayare, Carter, Eisenson and Dr. Blattler attended all meetings of
the Board. Mr. Feiner attended three meetings of the Board. Mr. Skaletsky
attended one.
COMPENSATION OF DIRECTORS
Non-employee Directors are entitled to receive cash compensation of $1,500
per Board meeting attended, although no such fees were paid during fiscal years
1999, 1998, and prior to April 12, 2000. Subsequent to April 12, 2000 payments
were made to certain Directors. Directors are also reimbursed for travel
expenses incurred with respect to attending Board meetings. No compensation is
paid for attendance at, or activities related to, Audit or Compensation
Committee meetings.
Under the Company's Restated Stock Option Plan, each non-employee Director,
upon first being elected or appointed to the Board after July 9, 1992, and on
every fourth anniversary thereof (assuming he remains a non-employee director),
will receive options to purchase 10,000 shares of Common Stock. Further, the
Board may also vote, at its discretion, to issue additional options as deemed
appropriate. In that regard, the Board voted to grant options to purchase 25,000
and 50,000 shares of Common Stock to each non-employee director in December 1997
and July 1998, respectively. In July 1998, the Board also voted to grant options
to purchase 50,000 shares of stock to any new non-employee director, if and when
elected to the Board. All options granted under the Plan have ten year terms and
exercise prices which are equal to the fair market value of the Common Stock on
the date of grant. Total option grants to date to the Company's current
non-employee Directors are as follows:
<TABLE>
<CAPTION>
OPTIONS GRANTED
---------------------------------------------------------------
GRANT DATE EXERCISE PRICE MR. CARTER MR. EISENSON(1) MR. FEINER(6) MR. SKALETSKY
---------- -------------- ---------- --------------- ------------- -------------
<S> <C> <C> <C> <C> <C>
July 2, 1992(2).......... $11.50 -- 10,000 10,000 --
July 2, 1996(2).......... 4.38 -- 10,000 10,000 --
June 17, 1997(2)(3)...... 1.63 10,000 -- -- --
December 31, 1997(4)..... 0.84 25,000 25,000 25,000 --
July 29, 1998(4)......... 1.38 50,000 50,000 50,000 --
March 14, 2000(5)........ 11.37 -- -- -- 60,000
------- ------ ------ ------
85,000 95,000 95,000 60,000
======= ====== ====== ======
</TABLE>
---------------
(1) Pursuant to an agreement among the Company, Aeneas Venture Corporation and
Mr. Eisenson, grants of stock options in respect of Mr. Eisenson's service
as a Director are granted directly to Aeneas Venture Corporation. His
Director fees are also paid to Aeneas Venture Corporation.
13
<PAGE> 17
(2) These options become exercisable as to one-quarter of the shares each year
after issuance beginning one year from the date of grant.
(3) Options granted upon Mr. Carter's election to the Board.
(4) These options become exercisable as to one-third of the shares each year
after issuance beginning one year from the date of grant.
(5) Options granted upon Mr. Skaletsky's election to the Board.
(6) Pursuant to an arrangement between Mr. Feiner and Inco Limited, Mr. Feiner
has assigned to Inco Limited options to acquire 53,334 of the 95,000 shares
covered by said options.
A plurality of the votes cast at the Meeting is required to elect each
nominee as a Director.
THE BOARD OF DIRECTORS RECOMMENDS THAT THE NUMBER OF DIRECTORS BE FIXED AT SIX
AND RECOMMENDS THE ELECTION OF THE NOMINEES AS DIRECTORS.
CERTAIN TRANSACTIONS
The holder of approximately 533,841 shares of Common Stock (the
"Registrable Securities") is entitled to certain rights to register such shares
under the Securities Act of 1933, as amended, (the "Securities Act") for sale to
the public pursuant to a Registration Rights Agreement by and among the Company
and the holders of Registrable Securities, as amended (the "Registration Rights
Agreement"). The holder of Registrable Securities is Aeneas Venture Corporation.
Such holder has the right to require the Company, on not more than two
occasions, whether or not the Company proposes to register any of its Common
Stock for sale, to register all or part of their shares for sale to the public
under the Securities Act, subject to certain conditions and limitations. In
addition, the holder of Registrable Securities may require the Company to
register all or part of their shares on Form S-3 (or a successor short form of
registration) if the Company then qualifies for use of such form, subject to
certain conditions and limitations. The Registration Rights Agreement was
amended on October 9, 1991 to limit the circumstances pursuant to which the
registration rights granted thereunder may be transferred to third parties and
to amend certain procedural requirements.
As part of an agreement entered into in July 1997 between the Company, ATI,
and BioChem Pharma Inc. ("BioChem"), BioChem received warrants to purchase
shares of Common Stock equal to the amount invested in ATI over a three-year
period. These warrants became exercisable at the end of the three-year period at
the market price of the Common Stock when the warrants are exercised. Pursuant
to a registration rights agreement between the Company and BioChem, at the end
of the three-year period BioChem is entitled to certain rights to require the
Company to register for sale to the public under the Securities Act all
registrable securities. As of September 30, 2000, warrants to purchase Common
Stock equal to the $11.125 million invested as of that date have been issued to
BioChem. No additional warrants will be issued under this agreement.
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires
the Company's Directors and executive officers, and persons holding more than
10% of the Common Stock, to file with the Securities and Exchange Commission
(the "SEC") initial reports of ownership and reports of changes in ownership of
Common Stock. Executive officers, Directors and greater than 10% shareholders
are required by SEC regulation to furnish the Company with copies of all Section
16(a) forms they file.
To the Company's knowledge, based solely on review of the copies of such
reports furnished to it and written representations that no other reports were
required, during the fiscal year ended June 30, 2000, the
14
<PAGE> 18
Company's executive officers, Directors and greater than 10% beneficial owners
of its Common Stock complied with all applicable Section 16(a) filing
requirements.
INDEPENDENT AUDITORS
PricewaterhouseCoopers LLP, independent accountants, audited the Company's
financial statements for the fiscal year ended June 30, 2000. The Company
expects that representatives of PricewaterhouseCoopers LLP will be present at
the Meeting, with the opportunity to make a statement if they so desire, and
will be available to respond to appropriate questions. The Company has selected
PricewaterhouseCoopers LLP, to audit the Company's financial statements for the
fiscal year ended June 30, 2001.
SHAREHOLDER PROPOSALS AND OTHER MATTERS
In order to be considered for inclusion in the proxy statement distributed
to shareholders prior to the Company's annual meeting in 2001, the Company must
receive a shareholder proposal no later than June 19, 2001. Proposals should be
delivered in writing to ImmunoGen, Inc., 128 Sidney Street, Cambridge,
Massachusetts 02139. One or more shareholders who hold at least a one-tenth part
in interest of the capital stock entitled to vote at the meeting and who do not
wish to include their proposal in such proxy statement but who wish to present a
proposal at the Company's annual meeting of shareholders in 2001, must notify
the Company in writing at the above-referenced address no later than October 25,
2001. All other shareholders who wish to present a proposal at such annual
meeting must notify the Company in writing at the above-referenced address no
later than August 31, 2001 in order for their proposal to be considered timely
for purposes of Rule 14a-4 under the Securities Exchange Act of 1934, as
amended.
The Board does not know of any other matters which will be brought before
the Meeting. If other business is properly presented for consideration at the
Meeting, it is intended that the shares represented by the enclosed Proxy will
be voted in accordance with their judgment on such matters.
In order that your shares may be represented if you do not plan to attend
the meeting, and in order to assure the required quorum, please complete, sign,
date and return your Proxy promptly.
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The following document filed by the Company with the Commission is
incorporated herein by reference:
Items 6, 7, 8 and 9 of the Company's Annual Report on Form 10-K for the
fiscal year ended June 30, 2000, filed pursuant to Section 13 or 15(d) of the
1934 Act (File Number 0-17999).
By order of the Board of Directors
JONATHAN L. KRAVETZ, ESQ.
Clerk
October 17, 2000
15
<PAGE> 19
PROXY IMMUNOGEN, INC. PROXY
PROXY SOLICITED BY THE BOARD OF DIRECTORS
OF IMMUNOGEN, INC. FOR THE
ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD ON NOVEMBER 14, 2000
The undersigned hereby acknowledges receipt of the Notice of Annual Meeting of
Shareholders and Proxy Statement dated October 17, 2000, and does hereby appoint
Mitchel Sayare and James Phayre, or either of them, the undersigned's
attorneys-in-fact and proxies, with full power of substitution in each, for and
in the name of the undersigned, with all the powers the undersigned would
possess if personally present, hereby revoking any proxy heretofore given, to
appear and represent and vote all shares of Common Stock of ImmunoGen, Inc.
which the undersigned would be entitled to vote if personally present at the
Annual Meeting of Shareholders to be held at the offices of the Company, 128
Sidney St., Cambridge, Massachusetts on Tuesday, November 14, 2000, at 10:00
a.m., Boston time, and at any adjournments thereof.
PLEASE FILL IN REVERSE SIDE AND MAIL IN THE ENCLOSED ENVELOPE
--------------------------------------------------------------------------------
-FOLD AND DETACH HERE-
<PAGE> 20
THE SHARES REPRESENTED HEREBY WILL BE VOTED AS Please mark [X]
DIRECTED HEREIN. IF NO DIRECTION IS INDICATED, your vote
SUCH SHARES WILL BE VOTED FOR ITEM 1 AND ITEM 2. as indicated
in this example
Item 1. Election of Directors:
Mitchel Sayare, Walter A. Blattler, David
W. Carter, Michael R. Eisenson, Stuart F.
Feiner, and Mark Skaletsky
<TABLE>
<CAPTION>
FOR ALL WITHHOLD UPDATE DIRECTORS
NOMINEES LISTED AUTHORITY I plan to attend the meeting. [ ]
TO THE RIGHT to vote for
(except those crossed out) all nominees
<S> <C> <C> <C>
[ ] [ ]
</TABLE>
In their discretion the proxies are authorized to vote upon such other business
as may properly come before the meeting or any adjournments thereof.
This proxy may be revoked in writing at any time prior to the voting thereof.
Please date and sign exactly as name appears on this card. Joint owners should
each sign. Please give full title when signing as executor, administrator,
trustee, attorney, guardian for a minor, etc. Signatures for corporations and
partnerships should be in the corporate or firm name by a duly authorized
person. Please return this proxy promptly in the enclosed envelope.
Signature: ________________________
Date: _____________________________
Signature: ________________________
Date: _____________________________
--------------------------------------------------------------------------------
-FOLD AND DETACH HERE-
